Raised Intracranial Pressure Alters Cranial Nociception Which Can Be Rescued by Glucagon Like Peptide 1 Receptor Agonism and CGRP Antagonism In Vivo
Creator
Olivia Grech; Eloisa Rubio-Beltran; Emily Stanyer; Alejandro Labastida-Ramirez; Daniel Fulton; Gareth Lavery; Lisa Hill; Philip Holland; Alexandra Sinclair
Affiliation
(OG) (AS) Translational Brain Science, University of Birmingham; (ER) (AL) (PH) Headache Group, King's College London; (ES) Sleep and Circadian Neuroscience Institute, University of Oxford; (DF) Institute of Inflammation and Ageing, University of Birmingham; (GL) Department of Biosciences, Nottingham Trent University; (LH) Institute of Clinical Sciences, University of Birmingham
Subject
High Intracranial Pressure/headache; Pseudotumor Cerebri
Description
Raised intracranial pressure (ICP) is a feature of Idiopathic Intracranial Hypertension (IIH), however, headache mechanisms are unknown, and targeted therapies are lacking. This study investigated headache mechanisms in raised ICP and the effects of; a) reducing ICP with glucagon-like peptide-1 (GLP-1) receptor agonist Exenatide b) attenuation with calcitoningene related peptide (CGRP).
Date
2024-03
References
None provided.
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2024 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting: Scientific Platform: Session II
